ADXN vs. LSTA, ITRM, DRRX, ONCT, INDP, GDTC, SNSE, BFRG, NRSN, and UBX
Should you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Lisata Therapeutics (LSTA), Iterum Therapeutics (ITRM), DURECT (DRRX), Oncternal Therapeutics (ONCT), Indaptus Therapeutics (INDP), CytoMed Therapeutics (GDTC), Sensei Biotherapeutics (SNSE), Bullfrog AI (BFRG), NeuroSense Therapeutics (NRSN), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical preparations" industry.
Lisata Therapeutics (NASDAQ:LSTA) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings.
Addex Therapeutics has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Addex Therapeutics received 7 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Lisata Therapeutics an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
In the previous week, Lisata Therapeutics had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.65 beat Lisata Therapeutics' score of 0.39 indicating that Lisata Therapeutics is being referred to more favorably in the media.
Lisata Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.
Lisata Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 455.56%. Given Addex Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Lisata Therapeutics is more favorable than Addex Therapeutics.
Lisata Therapeutics has a net margin of 0.00% compared to Lisata Therapeutics' net margin of -653.33%. Addex Therapeutics' return on equity of -38.06% beat Lisata Therapeutics' return on equity.
8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 21.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Lisata Therapeutics beats Addex Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Addex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Addex Therapeutics Competitors List
Related Companies and Tools
